Abstract
Background: The patients with MuSK antibody (MuSK-Ab) positive myasthenia gravis (MG) show distinct responses to acetylcholinesterase inhibitor (AChEI), such as less effective therapeutic response to AChEI and more frequent nicotinic side effects and negative result of diagnostic AChEI test. Some MuSK-Ab positive MG patients experience overt worsening after AChEI treatment. In addition, the compound muscle action potential with extradischarges (CMAP-EDs), elecrophysiologic feature of cholinergic neuromuscular hyperactivity, may develop in the MuSK-Ab positive MG patients with usual therapeutic dose of AChEI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
